Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer

Immunotherapy has revolutionized the treatment of advanced non–small-cell lung cancer (NSCLC). In two phase III trials (CheckMate 017 and CheckMate 057), nivolumab showed an improvement in overall survival (OS) and favorable safety versus docetaxel in patients with previously treated, advanced squam...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Clin Oncol
Главные авторы: Borghaei, Hossein, Gettinger, Scott, Vokes, Everett E., Chow, Laura Q. M., Burgio, Marco Angelo, de Castro Carpeno, Javier, Pluzanski, Adam, Arrieta, Oscar, Frontera, Osvaldo Arén, Chiari, Rita, Butts, Charles, Wójcik-Tomaszewska, Joanna, Coudert, Bruno, Garassino, Marina Chiara, Ready, Neal, Felip, Enriqueta, García, Miriam Alonso, Waterhouse, David, Domine, Manuel, Barlesi, Fabrice, Antonia, Scott, Wohlleber, Markus, Gerber, David E., Czyzewicz, Grzegorz, Spigel, David R., Crino, Lucio, Eberhardt, Wilfried Enst Erich, Li, Ang, Marimuthu, Sathiya, Brahmer, Julie
Формат: Artigo
Язык:Inglês
Опубликовано: American Society of Clinical Oncology 2021
Предметы:
ORIGINAL REPORTS
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC8078445/
https://ncbi.nlm.nih.gov/pubmed/33449799
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.01605
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы